Renée Bazin

Dr. Renée Bazin


Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2013 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
ISIsabelle St-Amour
Isabelle St-Amour
IPIsabelle Paré
Isabelle Paré
WAWael Alata
Wael Alata
KCKatherine Coulombe
Katherine Coulombe
CRCassandra Ringuette-Goulet
Cassandra Ringuette-Goulet
FCFrederic Calon
Frederic Calon
Intravenous immunoglobulin (IVIg) is currently evaluated in clinical trials for the treatment of various disorders of the central nervous system. To assess its capacity to reach central therapeutic targets, the brain bioavailability of IVIg must be determined. We thus quantified the passage of IVIg through the blood–brain barrier (BBB) of C57Bl/6 mice using complementary quantitative and qualitative methodologies. As determined by enzyme-linked immunosorbent assay, a small proportion of systemically injected IVIg was detected in the brain of mice (0.009±0.001% of injected dose in the cortex) whereas immunostaining revealed localization mainly within microvessels and less frequently in neurons. Pharmacokinetic analyses evidenced a low elimination rate constant (0.0053 per hour) in the cortex, consistent with accumulation within cerebral tissue. In situ cerebral perfusion experiments revealed that a fraction of IVIg crossed the BBB without causing leakage. A dose-dependent decrease of brain uptake was consistent with a saturable blood-to-brain transport mechanism. Finally, brain uptake of IVIg after a subchronic treatment was similar in the 3xTg-AD mouse model of Alzheimer disease compared with nontransgenic controls. In summary, our results provide evidence of BBB passage and bioavailability of IVIg into the brain in the absence of BBB leakage and in sufficient concentration to interact with the therapeutic targets.

6 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
SSSilvia Selleri
Silvia Selleri
PBPanojot Bifsha
Panojot Bifsha
SCSara Civini
Sara Civini
CPConsiglia Pacelli
Consiglia Pacelli
MDMame Massar Dieng
Mame Massar Dieng
EHElie Haddad
Elie Haddad
Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming

26 November 2020 in Blood
Verified
Journal Article
Open access
PDF file
JPJosée Perreault
Josée Perreault
TTTony Tremblay
Tony Tremblay
MFMarie-Josée Fournier
Marie-Josée Fournier
MDMathieu Drouin
Mathieu Drouin
GBGuillaume Beaudoin-Bussières
Guillaume Beaudoin-Bussières
RBRenée Bazin
Renée Bazin
Perreault and colleagues examined antibody titers in sequential samples from serum donors recovering from COVID-19 and demonstrated that antibody titers fall over 3-4 months. These results have important implications for convalescent serum collection and seroprevalence studies.

1 March 2021 in Cell Reports
Verified
Journal Article
Open access
RGRomain Gasser
Romain Gasser
MCMarc Cloutier
Marc Cloutier
JPJérémie Prévost
Jérémie Prévost
CFCorby Fink
Corby Fink
ÉDÉric Ducas
Éric Ducas
AFAndrés Finzi
Andrés Finzi
Characterization of the humoral response to SARS-CoV-2, the etiological agent of COVID-19, is essential to help control the infection. The neutralization activity of plasma from patients with COVID-19 decreases rapidly during the first weeks after recovery. However, the specific role of each immunoglobulin isotype in the overall neutralizing capacity is still not well understood. In this study, we select plasma from a cohort of convalescent patients with COVID-19 and selectively deplete immunoglobulin A, M, or G before testing the remaining neutralizing capacity of the depleted plasma. We find that depletion of immunoglobulin M is associated with the most substantial loss of virus neutralization, followed by immunoglobulin G. This observation may help design efficient antibody-based COVID-19 therapies and may also explain the increased susceptibility to SARS-CoV-2 of autoimmune patients receiving therapies that impair the production of immunoglobulin M (IgM).

20 July 1999 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
HKHabib Khoudi
Habib Khoudi
SLSerge Laberge
Serge Laberge
JFJean-Marc Ferullo
Jean-Marc Ferullo
YCYves Castonguay
Yves Castonguay
GAGuy Allard
Guy Allard
LVLouis‐P Vézina
Louis‐P Vézina

1 May 2005 in Molecular Immunology
Verified
Journal Article
Closed access
RLRéal Lemieux
Réal Lemieux
RBRenée Bazin
Renée Bazin
SNSonia Néron
Sonia Néron